Q-Line Biotech IPO
Price band
₹326 – ₹343
Lot size
400 shares
Min investment
₹1,37,200
Issue size
₹214.48 Cr
IPO schedule
| Open date | 21 May 2026 |
| Close date | 25 May 2026 |
| UPI mandate cut-off | 25 May 2026 |
| Allotment finalisation | 26 May 2026 |
| Refund initiation | 27 May 2026 |
| Shares credited to demat | 27 May 2026 |
| Listing date | 29 May 2026 |
| Mandate end date | 9 Jun 2026 |
| Anchor lock-in (50%) | 24 Jun 2026 |
| Anchor lock-in (remaining) | 23 Aug 2026 |
Issue size
Grey Market Premium (GMP)
GMP is an unofficial, unregulated indicator and not a reliable predictor of listing price. Source: IPO Watch.
Subscription status
Reserved and applied figures are in crore shares.
About Q-Line Biotech
Q-Line Biotech Limited is an in-vitro diagnostics (IVD) company engaged in the manufacturing and trading of biochemistry reagents, diagnostic instruments and consumables used in healthcare testing and laboratory applications. The company operates multiple manufacturing facilities in Uttar Pradesh and Delhi and offers products across categories such as ELISA, molecular diagnostics, chemiluminescence immunoassay (CLIA), immuno fluorescence assay (IFA), nucleic acid extraction kits and PCR-based diagnostic kits. Its product portfolio includes tests for infectious diseases, thyroid disorders, cardiac markers and other clinical conditions. The company generates revenue primarily through the sale of its diagnostic products and instruments, largely through a network of distributors, including group entity POCT Services. Q-Line Biotech also focuses on research and development through its subsidiary, Q-Line Innovations Private Limited, which works on developing diagnostic and scientific equipment and consumables.
Strengths
- Q-Line Biotech has established manufacturing capabilities with a focus on R&D and quality control.
- The company offers a diversified product portfolio across multiple IVD segments.
- It has a widespread distribution network across all four regions of India.
- The company has long-standing relationships with customers in the diagnostics industry.
- Q-Line Biotech has shown a track record of healthy financial performance.
Risks
- Any disruption at its manufacturing or R&D facilities could affect operations and revenue.
- The company depends on third-party suppliers for key raw materials and equipment.
- A large share of revenue comes from a few major customers.
- Failure to maintain product quality could lead to recalls, penalties, or reputational damage.
- Delays in regulatory approvals or registrations may impact business operations.
Use of proceeds
| Repayment of borrowings | ₹90 (41.96%) Cr |
| General corporate purposes | ₹30.98 (14.45%) Cr |
IPO information is sourced from public feeds and shown for general information only. It is not a recommendation to apply for this or any IPO. IPOs are equity investments and carry market risk; listing gains are not guaranteed and SME IPOs are especially volatile. Grey Market Premium (GMP) is unofficial and not endorsed by SEBI or the exchanges. Equity IPOs are applied for through a demat and trading account, not through mutual fund distribution services. Read the RHP and consult a SEBI-registered investment adviser before investing.